On November 20, 2019 Suzhou’s BrightGene Bio-Medical reported that completed a $74 million IPO on the Shanghai Star Exchange and climbed 141% higher in its first trading session, giving the company a market capitalization of $1.8 billion (Press release, ChinaBio, NOV 20, 2019, View Source [SID1234551555]). Founded in 2001, BrightGene develops novel drugs as well as hard-to-make generics, APIs and finished drugs. The company is developing immunoncology treatments, oral GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumors, and novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!